Data Foundry

Drug recalls 2026

Theophylline Extended-Release Tablets — Class II drug recall D-0111-2027

Ongoing recall by Brandywine Pharmaceuticals, LLC, reported 2026-11-04, distributed nationwide. CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

Recall numberD-0111-2027
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmBrandywine Pharmaceuticals, LLC, West Chester, PA, United States
Recall initiated2026-10-06
Classified2026-10-29
Reported by FDA2026-11-04
DistributedNationwide (US)
Reason classescgmp, specification failure
NDC71321-0501-10
Lot numbers405620
Expiration dates2028-03-31

Product

Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.

Reason for recall

CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0111-2027. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-11-10. Not affiliated with or endorsed by FDA. Not medical or legal advice.